dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Giannakakis, T. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Athanasiades, A. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Damigos, D. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Giannakakis, T. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Athanasiades, A. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Damigos, D. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:09Z | |
dc.date.available | 2018-06-22T09:54:09Z | |
dc.date.issued | 1998 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42216 | |
dc.description.abstract | Tropisetron is a novel selective antagonist of the type-3 serotonin (5- HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. Epirubicin in doses of >100 mg/m2 has a high emetogenic potential. This study was designed to determine whether a single intravenous administration of tropisetron could prevent acute nausea and vomiting in patients treated with high dose epirubicin. Forty chemotherapy naive breast cancer patients treated with epirubicin at a dose of 110 mg/m2 on an outpatient basis were enrolled in the study. Tropisetron 5 mg i.v. was used as antiemetic prophylaxis. 'On demand' treatment with tropisetron 5 mg p.os was used for the rescue of patients who failed on the initial iv dose. Complete control of acute nausea and vomiting had 62.5% (95% C.1.47.2 - 77.8), partial control 15% (95% C.1.3.8-26.2) and 22.5% (95% C.1. 9.3-35.7) insufficient control or failure. Headache was the most common adverse event reported in 3 patients (7.5%) and constipation in 2 patients (5%). Interestingly, patients with a negative experience of nausea and vomiting during pregnancy and those treated for metastatic disease, had a better control of chemotherapy-induced nausea and vomiting. In conclusion, a single 5 mg i.v. dose of tropisetron is safe and effective in preventing acute emesis in patients treated with high dose epirubicin. | en |
dc.language.iso | eng | en |
dc.source | Journal of Experimental and Clinical Cancer Research | en |
dc.subject | Article | en |
dc.subject | Female | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast cancer | en |
dc.subject | Breast neoplasms | en |
dc.subject | Middle aged | en |
dc.subject | Chemotherapy | en |
dc.subject | Priority journal | en |
dc.subject | Clinical article | en |
dc.subject | Drug efficacy | en |
dc.subject | Drug safety | en |
dc.subject | Granulocyte colony-stimulating factor | en |
dc.subject | Treatment outcome | en |
dc.subject | Antineoplastic activity | en |
dc.subject | Intravenous | en |
dc.subject | Epirubicin | en |
dc.subject | Adjuvant | en |
dc.subject | Injections | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Vomiting | en |
dc.subject | Nausea | en |
dc.subject | Antineoplastic | en |
dc.subject | Combined modality therapy | en |
dc.subject | Indoles | en |
dc.subject | Antibiotics | en |
dc.subject | Acute disease | en |
dc.subject | Antiemetics | en |
dc.subject | 5-ht3 receptor antagonist | en |
dc.subject | Acute emesis | en |
dc.subject | Constipation | en |
dc.subject | Headache | en |
dc.subject | High dose epirubicin | en |
dc.subject | Serotonin 3 antagonist | en |
dc.subject | Tropisetron | en |
dc.title | Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 17 | |
dc.description.issue | 1 | |
dc.description.startingpage | 71 | |
dc.description.endingpage | 76 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |